XML 40 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 27, 2019
Sep. 28, 2018
Statement of Cash Flows [Abstract]    
Net income $ 252,269 $ 329,981
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 6,088 2,876
Stock-based compensation 40,747 28,330
401(k) matching contributions made in common stock 4,079 3,232
Amortization and other changes in right-of-use assets (6,367) 2,732
Deferred income taxes 56,339 0
Gain on other equity investments (730) (209)
Accretion of investments, net and other (3,970) (1,423)
Changes in operating assets and liabilities:    
Trade receivables, net (7,017) (12,707)
Other receivables 2,469 (2,938)
Inventory, net (3,528) (3,776)
Current portion of unbilled collaboration revenue (2,640) (32,673)
Prepaid expenses and other current assets 527 (3,529)
Other long-term assets (6,294) (542)
Accounts payable (2,708) (1,248)
Accrued compensation and benefits (429) 6,210
Accrued clinical trial liabilities 12,099 (891)
Rebates and fees due customers 1,828 4,124
Accrued collaboration liability 554 (577)
Current and long-term deferred revenue 3,592 (1,548)
Long-term portion of lease liabilities 6,087 (974)
Other current and long-term liabilities 15,940 (3,321)
Net cash provided by operating activities 368,935 311,129
Cash flows from investing activities:    
Purchases of property and equipment (5,575) (30,403)
Proceeds from sale of property and equipment 0 308
Purchases of investments (887,698) (368,304)
Proceeds from maturities of investments 422,419 231,204
Proceeds from sale of investments 13,078 11,935
Proceeds from other equity investments 730 209
Net cash used in investing activities (457,046) (155,051)
Cash flows from financing activities:    
Proceeds from exercise of stock options 14,811 10,390
Proceeds from employee stock purchase plan 4,145 3,650
Taxes paid related to net share settlement of equity awards (3,369) (3,205)
Principal payments on financing lease obligation (34) 0
Net cash provided by financing activities 15,553 10,835
Net (decrease) increase in cash, cash equivalents and restricted cash (72,558) 166,913
Cash, cash equivalents and restricted cash at beginning of period 315,875 188,314
Cash, cash equivalents and restricted cash at end of period 243,317 355,227
Supplemental cash flow disclosure:    
Right-of-use assets obtained in exchange for lease obligations [1] 12,944 17,180
Unpaid liabilities incurred to acquire Property and equipment 159 1,281
Unpaid liabilities incurred to acquire investments $ 8,961 $ 0
[1]
Amounts for the nine months ended September 30, 2019 include receipt of a tenant incentive payment and an amendment to our existing lease for office and research space. Amounts for the nine months ended September 30, 2018 include the transition adjustment for the adoption of Topic 842.